Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.46 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | G6PD | P11413 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5289140 | 1.00 | PTGS2 (0.52) | PTGS2HTR2AHTR2CHTR2BTAAR1 | |
| SCHEMBL26056853 | 0.82 | HTR2A (0.38) | PTGS2HTR2AHTR2CHTR2BTAAR1 | |
| SCHEMBL5572443 | 0.80 | PTGS2 (0.59) | PTGS2HTR2AHTR2CHTR2B | |
| SCHEMBL10998613 | 0.80 | PTGS2 (0.59) | PTGS2HTR2AHTR2CHTR2B | |
| SCHEMBL30559576 | 0.80 | CA2 (0.60) | TAAR1 | |
| SCHEMBL8828295 | 0.80 | CA2 (0.60) | TAAR1 | |
| SCHEMBL1023836 | 0.80 | CA2 (0.60) | TAAR1 | |
| SCHEMBL1026086 | 0.80 | CA2 (0.60) | TAAR1 | |
| Hydrochloric Acid SCHEMBL23524379 | 0.79 | CA2 (0.58) | SIGMAR1 | |
| SCHEMBL4390554 | 0.77 | TAAR1 (0.48) | TAAR1SLC18A2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150025063-A1 | Antiparkinsonian Action of Phenylisopropylamines | UNIV DUKE (US) | 2015-01-22 | — | — | US | disclosed |
| US-8877802-B2 | Antiparkinsonian action of phenylisopropylamines | Duke Univerity (US) | 2014-11-04 | — | — | US | disclosed |
| WO-2007016190-A2 | ANTIPARKINSONIAN ACTION OF PHENYLISOPROPYLAMINES | DUKE UNIVERSITY (US) | 2007-02-08 | — | — | WO | disclosed |
| US-20070027208-A1 | Antiparkinsonian Action of Phenylisopropylamines | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027208-A1 | Antiparkinsonian Action of Phenylisopropylamines | PNMT, SNCA, COMT | PTGS2 1270/4885HTR2A 18/4885HTR2C 44/4885 |
| US-20150025063-A1 | Antiparkinsonian Action of Phenylisopropylamines | PNMT, SNCA, COMT | PTGS2 1270/4885HTR2A 18/4885HTR2C 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.